Status:
UNKNOWN
Treatment of Challenging Macular Holes Using Plasma Rich in Growth Factors
Lead Sponsor:
Minia University
Conditions:
Macular Holes
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Aim of the Study:To report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes
Detailed Description
Challenging full thickness macular holes ( FTMH) include : Recurrent FTMH Persistent (refractory) FTMH Macular holes in eyes with pathological myopia Large macular holes with an inner diameter of mor...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Challenging FTMH which include Recurrent macular holes Persistent(refractory) macular holes Macular holes in eyes with pathological myopia Large macular holes with an inner diameter of more than 650 µm
Exclusion
- 1-Corneal opacities 2-Glaucomatous patients 3-Co-existing macular pathology ( e.g. diabetic retinopathy, vein occlusion and age related macular degeneration ) 4-History of PPV for any reason other than FTMH
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06115005
Start Date
June 1 2022
End Date
August 1 2024
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minia University Hospital
Minya, Egypt